Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CCR9 | P51686 | 5/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7595506 | 0.88 | FFAR4 (0.57) | FFAR4CCR9KEAP1NFE2L2FBP1 | |
| SCHEMBL26530288 | 0.82 | FFAR4 (0.54) | FFAR4GAAKMT2ACCR9 | |
| SCHEMBL26536602 | 0.82 | WDR5 (0.56) | FFAR4GAAKMT2ACCR9 | |
| SCHEMBL7573010 | 0.81 | FFAR4 (0.52) | FFAR4CCR9KEAP1NFE2L2 | |
| SCHEMBL9321921 | 0.79 | PTPN1 (0.54) | FFAR4KMT2A | |
| SCHEMBL26537109 | 0.78 | FFAR4 (0.56) | FFAR4GAAKMT2ACCR9FBP1 | |
| SCHEMBL7570513 | 0.77 | FFAR4 (0.64) | FFAR4 | |
| SCHEMBL5597750 | 0.76 | FFAR4 (0.53) | FFAR4CCR9FBP1 | |
| SCHEMBL7590053 | 0.76 | FFAR4 (0.59) | FFAR4GAAKMT2ACCR9FBP1 | |
| SCHEMBL7569763 | 0.76 | FFAR4 (0.59) | FFAR4GAAKMT2ACCR9FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | FFAR4 2391/4885GAA 1944/4885KMT2A 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.